Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial

Sponsor
Zagazig University
Study ID
NCT07820111
Phase
PHASE3
Status
Completed

Conditions

  • Obese Diabetics
  • Obese Non Diabetic

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

Study Details

titel : Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical Trial Abstract : Background: This study that highlights the different effects of most used three GLP-RA Dulaglutide, Semaglutide, Tirazepetide among diabetic and non -diabetic participant as the well-known fact that they don't have only weight recuing effect but also many different effects on metabolic process including insulin sensitivity, lipid profile and NASH. Materials and Methods: This is a randomized controlled study involving a total of 159 participants, divided into 75 non-diabetic and 84 diabetic obese individuals. Participants were assigned to three drug groups, each receiving a once-weekly dose of Dulaglutide, Semaglutide, or Tirzepatide for a period of 24 weeks. Each drug group consisted of 53 individuals, subdivided into 25 non-diabetic and 28 diabetic participants. Measurements were taken at three time points: pretreatment, 3 months post-treatment, and 6 months post-treatment. Each participant underwent a complete physical exam, and data was collected on weight, BMI, age, and sex and Laboratory tests. , also repeated measurements were taken at 3 and 6 months post-treatment. on metabolic processes, weight reduction, and insulin sensitivity, particularly in diabetic individuals, as well as effects on lipid profiles and liver enzymes, weight reduction, BMI, HbA1c, TYG-index, triglycerides, and HDL-C levels. total cholesterol (Tc) and liver enzymes. Data were collected, and statistical analyses were conducted afterward.

Key Dates

First listed
Sep 15, 2026
Start date
Oct 18, 2025
Status verified
Sep 2026
Primary completion
Mar 17, 2026
Completion
Mar 17, 2026

Study Design

Enrollment
159 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: obese , non diabetic ,recieve dulaglutide
    GLP1-RA
  • Active Comparator: obese , non diabetic ,receive SEMAGLUTIDE
    GLP1-RA
  • Active Comparator: obese , non diabetic ,receive TIRAZEPETIDE
    GLP1-RA
  • Active Comparator: obese , diabetic ,recieve dulaglutide
    GLP1-RA
  • Active Comparator: obese , diabetic ,receive SEMAGLUTIDE
    GLP1-RA
  • Active Comparator: obese , diabetic ,receive TIRAZEPETIDE
    GLP1-RA

Primary Outcome Measure

change in body weight at 3 and 6 months [ Time Frame: 6-MONTH STUDY PERIOD ]

Related coverage on Hipa.ai